NCT04368988

Brief Summary

2019nCoV-101 is a 2-part, randomized, observer-blinded, placebo-controlled, Phase 1/2 trial. Part 1 (Phase 1) of the study is designed to evaluate the safety and immunogenicity of SARS-CoV-2 rS nanoparticle vaccine with or without Matrix-M adjuvant in 131 healthy participants ≥ 18 to 59 (inclusive) years of age at 2 sites in Australia. An interim analysis of Part 1 safety and immunogenicity will be performed prior to optional expansion to Part 2. Part 2 (Phase 2) of the study is designed to evaluate the immunogenicity, safety, and preliminary efficacy of a single construct of SARS-CoV-2 rS nanoparticle vaccine with Matrix-M adjuvant in up to 1,500 healthy participants ≥ 18 to 84 (inclusive) years of age at up to 40 sites across Australia and/or the United States.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,419

participants targeted

Target at P75+ for phase_1 covid19

Timeline
Completed

Started May 2020

Longer than P75 for phase_1 covid19

Geographic Reach
2 countries

18 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 24, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 30, 2020

Completed
25 days until next milestone

Study Start

First participant enrolled

May 25, 2020

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2022

Completed
Last Updated

April 10, 2023

Status Verified

April 1, 2023

Enrollment Period

2 years

First QC Date

April 24, 2020

Last Update Submit

April 6, 2023

Conditions

Outcome Measures

Primary Outcomes (11)

  • Participants with Solicited Adverse Events (AEs) - Phase 1

    Percentage of participants with solicited AEs (local, systemic) for 7 days following each primary vaccination (Days 0, 21) by severity score, duration, and peak intensity.

    28 days

  • Safety Laboratory Values (Serum Chemistry, Hematology) - Phase 1

    Safety laboratory values (serum chemistry, hematology) by FDA toxicity scoring (absolute and change from baseline where identified) at 7 days after each vaccination.

    28 days

  • Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) - Phase 1

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by enzyme-linked immunosorbent assay (ELISA) expressed as GMTs through Day 21.

    21 days

  • Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) - Phase 1

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by enzyme-linked immunosorbent assay (ELISA) expressed as GMTs through Day 35.

    35 days

  • Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs) - Phase 1

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs through Day 35.

    35 days

  • Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs) - Phase 1

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as SCRs through Day 35. SCR is the proportion of participants with ≥4-fold rises in ELISA units.

    35 days

  • Serum IgG Antibody Levels Expressed as GMEUs - Phase 2

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMTs for the two-dose regimens by dose at Day 35 regardless of baseline immune status and stratified by baseline immune status.

    Day 35

  • Serum IgG Antibody Levels Expressed as GMFRs - Phase 2

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs for the two-dose regimens by dose at Day 35 regardless of baseline immune status and stratified by baseline immune status.

    Day 35

  • Serum IgG Antibody Levels Expressed as SCRs - Phase 2

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as SCRs (≥4-fold rises) for the two-dose regimens by dose at Day 35 regardless of baseline immune status and stratified by baseline immune status.

    Day 35

  • Participants with Solicited Adverse Events (AEs) - Phase 2

    Percentage of participants with solicited AEs (local, systemic) for 7 days following each primary vaccination (Days 0 and 21) by severity score, duration, and peak intensity.

    28 days

  • Participants with Unsolicited AEs - Phase 2

    Percentage of participants with unsolicited AEs (eg, treatment-emergent, serious, suspected unexpected serious, those of special interest, all medically attended adverse events \[MAAEs\]) through the 35 days by Medical Dictionary of Regulatory Activities (MedDRA) classification, severity score, and relatedness.

    35 days

Secondary Outcomes (43)

  • Participants with Unsolicited AEs - Phase 1

    49 days

  • Participants with Abnormal Vital Signs - Phase 1

    21 days

  • Changes from Baseline in Body Temperature - Phase 1

    189 days

  • Changes from Baseline in Blood Pressure - Phase 1

    189 days

  • Changes from Baseline in Pulse Rate - Phase 1

    189 days

  • +38 more secondary outcomes

Study Arms (12)

Placebo - Phase 1

PLACEBO COMPARATOR

2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.

Other: Normal saline solution (NSS), Placebo - Phase 1

SARS-CoV-2 rS - 25 μg without Matrix-M - Phase 1

EXPERIMENTAL

2 doses of SARS-CoV-2 rS - 25 μg, 1 dose each on Days 0 and 21.

Biological: SARS-CoV-2 rS - Phase 1

SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 1

EXPERIMENTAL

2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.

Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1

SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 1

EXPERIMENTAL

2 doses of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.

Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1

SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M then Placebo - Phase 1

EXPERIMENTAL

1 dose of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (mixed together for injection), on Day 0 followed by 1 dose of Placebo on Day 21.

Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1

Placebo - Phase 2

PLACEBO COMPARATOR

3 doses of Placebo (Saline), 1 dose each on Days 0, 21, and 189.

Other: Normal saline solution (NSS), Placebo - Phase 2

SARS-CoV-2 rS - 5/5 μg + 50 μg Matrix-M - Phase 2

EXPERIMENTAL

2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.

Other: Normal saline solution (NSS), Placebo - Phase 2Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2

SARS-CoV-2 rS - Alternating 5/5 μg + 50 μg Matrix-M - Phase 2

EXPERIMENTAL

1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 1 dose of Placebo on Day 21 followed by 1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 189.

Other: Normal saline solution (NSS), Placebo - Phase 2Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2

SARS-CoV-2 rS - 25/25 μg + 50 μg Matrix-M - Phase 2

EXPERIMENTAL

2 doses of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.

Other: Normal saline solution (NSS), Placebo - Phase 2Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2

SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 2

EXPERIMENTAL

1 dose of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 2 doses of Placebo, 1 dose each on Days 21 and 189.

Other: Normal saline solution (NSS), Placebo - Phase 2Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2

SARS-CoV-2 rS - 5/5/5 μg + 50 μg Matrix-M - Phase 2

EXPERIMENTAL

3 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Day 0, Day 21, and Day 189.

Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2

SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 2

EXPERIMENTAL

1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 2 doses of Placebo, 1 dose each on Days 21 and 189.

Other: Normal saline solution (NSS), Placebo - Phase 2Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2

Interventions

Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS (0.6 mL) on Days 0 and 21.

SARS-CoV-2 rS - 25 μg without Matrix-M - Phase 1

Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Days 0 and 21.

Also known as: NVX-CoV2373
SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 1SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 1

Alternating intramuscular (deltoid) injections of placebo (0.6 mL) on Days 0 and 21.

Also known as: Sodium chloride solution for injection, 0.9%
Placebo - Phase 1

Intramuscular (deltoid) injections of placebo (0.5 mL).

Also known as: Sodium chloride solution for injection, 0.9%
Placebo - Phase 2SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 2SARS-CoV-2 rS - 25/25 μg + 50 μg Matrix-M - Phase 2SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 2SARS-CoV-2 rS - 5/5 μg + 50 μg Matrix-M - Phase 2SARS-CoV-2 rS - Alternating 5/5 μg + 50 μg Matrix-M - Phase 2

Intramuscular (deltoid) injection of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Day 0.

Also known as: NVX-CoV2373
SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M then Placebo - Phase 1

Intramuscular injection of placebo (0.6 mL) in alternate deltoid on Day 21.

Also known as: Sodium chloride solution for injection, 0.9%
SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M then Placebo - Phase 1

Intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL).

Also known as: NVX-CoV2373
SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 2SARS-CoV-2 rS - 25/25 μg + 50 μg Matrix-M - Phase 2SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 2SARS-CoV-2 rS - 5/5 μg + 50 μg Matrix-M - Phase 2SARS-CoV-2 rS - 5/5/5 μg + 50 μg Matrix-M - Phase 2SARS-CoV-2 rS - Alternating 5/5 μg + 50 μg Matrix-M - Phase 2

Eligibility Criteria

Age18 Years - 84 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy adult males or females between 18 and 59 years of age, inclusive, at screening. Healthy status will be determined by the investigator based on medical history, clinical laboratory results, vital sign measurements, and physical examination at screening.
  • The participant has a body mass index 17 to 35 kg/m2, inclusive, at screening.
  • Willing and able to give informed consent prior to study enrollment and comply with study procedures.
  • Female participants of childbearing potential (defined as any female who has experienced menarche and who is NOT surgically sterile \[ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy\] or postmenopausal \[defined as amenorrhea at least 12 consecutive months or documented plasma follicle-stimulating hormone (FSH) level ≥40 mIU/mL\]) must agree to be heterosexually inactive from at least 21 days prior to enrollment and through 6 months after the last vaccination OR agree to consistently use any of the described methods of contraception from at least 21 days prior to enrollment and through 6 months after the last vaccination.

You may not qualify if:

  • Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care, inclusive of changes in medication in the past 2 months indicating that chronic illness/disease is not stable (at the discretion of the investigator). This includes any current workup of undiagnosed illness that could lead to a new condition.
  • Chronic disease inclusive of: a) hypertension uncontrolled for age according to the Eighth Joint National Committee (JNC 8) guidelines; b) congestive heart failure by New York Heart Association (NYHA) functional classification of greater or equal to II; c) chronic obstructive pulmonary disease by Global Initiative for Obstructive Lung Disease (GOLD) classification of greater or equal to 2; d) recent (within 6 months prior to first study vaccination) exacerbation of coronary artery disease as manifested by cardiac intervention, addition of new cardiac medications for control of symptoms, or unstable angina; e) asthma (diagnosed by spirometry showing reversibility of disease and must meet at least the Step 1 classification with current prescription/use of medications to control symptoms); f) diabetes requiring use of medicine (insulin or oral) or not controlled with diet.
  • Participation in research involving an investigational product (drug/biologic/device) within 45 days prior to first study vaccination.
  • History of a confirmed diagnosis of SARS or COVID-19 disease (confirmed by a specific test for each disease) or known exposure to a SARS-CoV-2 positive confirmed close contact (eg, family member, housemate, daycare provider, aged parent requiring care), at the discretion of the investigator.
  • Currently working in an occupation with a high risk of exposure to SARS-CoV-2 (eg, healthcare worker, emergency response personnel).
  • Currently taking any product (investigational or off-label) for prevention of COVID-19 disease.
  • Positive rapid test for SARS-CoV-2 (either ELISA IgG or PCR) at screening or prior to first vaccination. Testing may be repeated during the screening period if exposure to SARS-CoV-2 is suspected, at the discretion of the investigator.
  • Received influenza vaccination within 14 days prior to first study vaccination, or any other vaccine within 4 weeks prior to first study vaccination.
  • Any autoimmune or immunodeficiency disease/condition (iatrogenic or congenital).
  • Chronic administration (defined as more than 14 continuous days) of immunosuppressant, systemic glucocorticosteroids, or other immune-modifying drugs within 90 days prior to first study vaccination; or anticipation of the need for immunosuppressive treatment within 6 months after last vaccination.
  • Received immunoglobulin, blood-derived products, or other immunosuppressant drugs within 90 days prior to first study vaccination.
  • Any acute illness concurrent or within 14 days prior to first study vaccination (medical history and/or physical examination) or documented temperature of \>38°C during this period. This includes respiratory or constitutional symptoms consistent with SARS-CoV-2 (COVID-19) exposure (ie, cough, sore throat, difficulty breathing).
  • Known disturbance of coagulation (iatrogenic or congenital).
  • Evidence of Hepatitis B or C or HIV by laboratory testing.
  • A positive test result for drugs of abuse (except a positive test result associated with prescription medication that has been reviewed and approved by the investigator) or alcohol at screening.
  • +33 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (18)

Meridian Clinical Research-(Savannah Georgia) - Platinum - PPDS - Phase 2

Savannah, Georgia, 31406, United States

Location

Advanced Clinical Research - Meridian - ERN-PPDS - Phase 2

Meridian, Idaho, 83642, United States

Location

Alliance for Multispecialty Research, LLC - Phase 2

Newton, Kansas, 67114, United States

Location

Alliance for Multispecialty Research, LLC - Phase 2

Wichita, Kansas, 67207, United States

Location

Central Kentucky Research Associates Inc - Phase 2

Lexington, Kentucky, 40509, United States

Location

Meridian Clinical Research-(Rockville Maryland) - Platinum - PPDS - Phase 2

Rockville, Maryland, 20854, United States

Location

Synexus Clinical Research US, Inc. - Cincinnati - Phase 2

Cincinnati, Ohio, 45236, United States

Location

Rapid Medical Research Inc - ERN-PPDS - Phase 2

Cleveland, Ohio, 44122, United States

Location

Paratus Clinical Research - Canberra - Phase 2

Bruce, Australian Capital Territory, 2617, Australia

Location

Paratus Clinical Research - Western Sydney - Phase 2

Blacktown, New South Wales, 2148, Australia

Location

Paratus Clinical Research - Central Coast - Phase 2

Kanwal, New South Wales, 2259, Australia

Location

Australian Clinical Research Network - Phase 2

Maroubra, New South Wales, 2035, Australia

Location

Scientia Clinical Research Limited - Phase 2

Randwick, New South Wales, 2031, Australia

Location

Q Pharm Pty Limited - Phase 1

Herston, Queensland, 4006, Australia

Location

University of the Sunshine Coast, Health Hub Morayfield - Phase 2

Morayfield, Queensland, 4506, Australia

Location

University of the Sunshine Coast - Phase 2

Sippy Downs, Queensland, 4556, Australia

Location

Barwon Health - Phase 2

Geelong, Victoria, 3220, Australia

Location

Center for Clinical Studies - Phase 1 and Phase 2

Melbourne, Victoria, 3181, Australia

Location

Related Publications (8)

  • Bangaru S, Jackson AM, Copps J, Fernandez-Quintero ML, Torres JL, Richey ST, Nogal B, Sewall LM, Torrents de la Pena A, Rehman A, Guebre-Xabier M, Girard B, Das R, Corbett-Helaire KS, Seder RA, Graham BS, Edwards DK, Patel N, Smith G, Ward AB. Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines. Cell Rep. 2025 Jul 22;44(7):115986. doi: 10.1016/j.celrep.2025.115986. Epub 2025 Jul 8.

  • Alves K, Plested JS, Galbiati S, Chau G, Cloney-Clark S, Zhu M, Kalkeri R, Patel N, Smith K, Marcheschi A, Pfeiffer S, McFall H, Smith G, Glenn GM, Dubovsky F, Mallory RM; Novavax 2019nCoV-101 Study Group. Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373. Vaccine. 2023 Jun 29;41(29):4280-4286. doi: 10.1016/j.vaccine.2023.05.051. Epub 2023 Jun 2.

  • Fries L, Formica N, Mallory RM, Zhou H, Plested JS, Kalkeri R, Moldovan I, Patel N, Albert G, Robinson M, Cho I, Chau G, Dubovsky F, Glenn GM; 2019nCoV-101 Study Group. Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination. J Infect Dis. 2023 Sep 15;228(6):734-741. doi: 10.1093/infdis/jiad163.

  • Mallory RM, Formica N, Pfeiffer S, Wilkinson B, Marcheschi A, Albert G, McFall H, Robinson M, Plested JS, Zhu M, Cloney-Clark S, Zhou B, Chau G, Robertson A, Maciejewski S, Hammond HL, Baracco L, Logue J, Frieman MB, Smith G, Patel N, Glenn GM; Novavax 2019nCoV101 Study Group. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2022 Nov;22(11):1565-1576. doi: 10.1016/S1473-3099(22)00420-0. Epub 2022 Aug 10.

  • Formica N, Mallory R, Albert G, Robinson M, Plested JS, Cho I, Robertson A, Dubovsky F, Glenn GM; 2019nCoV-101 Study Group. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial. PLoS Med. 2021 Oct 1;18(10):e1003769. doi: 10.1371/journal.pmed.1003769. eCollection 2021 Oct.

  • Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Logue J, Portnoff AD, Norton J, Guebre-Xabier M, Zhou B, Jacobson K, Maciejewski S, Khatoon R, Wisniewska M, Moffitt W, Kluepfel-Stahl S, Ekechukwu B, Papin J, Boddapati S, Jason Wong C, Piedra PA, Frieman MB, Massare MJ, Fries L, Bengtsson KL, Stertman L, Ellingsworth L, Glenn G, Smith G. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021 Jan 14;12(1):372. doi: 10.1038/s41467-020-20653-8.

  • Guebre-Xabier M, Patel N, Tian JH, Zhou B, Maciejewski S, Lam K, Portnoff AD, Massare MJ, Frieman MB, Piedra PA, Ellingsworth L, Glenn G, Smith G. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020 Nov 25;38(50):7892-7896. doi: 10.1016/j.vaccine.2020.10.064. Epub 2020 Oct 23.

  • Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020 Dec 10;383(24):2320-2332. doi: 10.1056/NEJMoa2026920. Epub 2020 Sep 2.

MeSH Terms

Conditions

COVID-19

Interventions

NVX-CoV2373 adjuvated lipid nanoparticleSodium ChlorideInjections

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium CompoundsDrug Administration RoutesDrug TherapyTherapeutics

Study Officials

  • Clinical Development

    Novavax

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 24, 2020

First Posted

April 30, 2020

Study Start

May 25, 2020

Primary Completion

June 1, 2022

Study Completion

June 1, 2022

Last Updated

April 10, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will not share

Locations